Operationalisation of ISIN-Level Freeze of Promoter Holdings

The circular operationalises the freezing of holdings of promoters and promoter group, including their associates, at the ISIN level under Regulation 24(i)(ea) of the SEBI (Buy-back of Securities) Regulations, 2018. The provision was inserted through the amendment to the Buy-back Regulations dated July 01, 2026. The freeze applies from the date of passing of the resolution by the board of directors or the special resolution, as applicable, until the closing of the buy-back offer.

Delhi Fire Service (Amendment) Bill, 2026

The Delhi Legislative Assembly Secretariat published the Delhi Fire Service (Amendment) Bill, 2026 (Bill No. 12 of 2026) for general information. The Bill was introduced in the Legislative Assembly of the National Capital Territory of Delhi on August 11, 2026. The Bill provides for further amendment of the Delhi Fire Service Act, 2007.

Establishment of New Indian Standards and Withdrawal of Superseded Standards by BIS

The Bureau of Indian Standards, Department of Consumer Affairs, notified that the Indian Standards specified in the Schedule were established on August 03, 2026. The standards specified in the fourth column of the Schedule, where applicable, shall remain in force concurrently until the withdrawal dates specified in the fifth column.

Central Motor Vehicles (Twelfth Amendment) Rules, 2026

The Ministry of Road Transport and Highways had published draft rules for further amendment of the Central Motor Vehicles Rules, 1989 vide G.S.R. 214(E), dated March 20, 2026, inviting objections and suggestions from persons likely to be affected.

CGRERA Clarification on Project Extension

The Chhattisgarh Real Estate Regulatory Authority issued Order No. 26/CGRERA/2026/2723 dated August 11, 2026 in continuation of Order No. 25/CGRERA/2026/2612 dated August 6, 2026.

CDSCO Clarification on Applications for Unapproved New Drugs

The Central Drugs Standard Control Organization (New Drugs Division) stated that various applications had been received for permission to import and market new drugs that were not approved anywhere in the world, where Phase III Global Clinical Trials (GCTs) were ongoing or had been completed with participation of Indian subjects. The matter was examined by an internal technical committee within CDSCO.

Schedule A Demo